Researchers combine GPS and sensor fusion to improve container stacking accuracy while cutting energy use in busy global ports.

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

In the latest escalation of the long-running dispute, up to 1270 workers will walk out of CSL’s Melbourne office, expressing anger at management’s response to union members voting down the company’s ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) will be reporting earnings this Tuesday after market close. Here’s what investors should know. Carlisle beat analysts’ revenue ...

The global biotech has lost $36bn in market value and axed its CEO, yet its interim boss insists CSL remains a ‘blue chip’ company. Battling lower vaccination rates in the US under the Trump ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

The global biotechnology company announced minutes before the market closed on Tuesday that Mr McKenzie would be immediately replaced by Gordon Naylor, a current CSL director who has held a number of ...